Comparison of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors use in Australia and Nova Scotia (Canada)

British Journal of Clinical Pharmacology

Volumn 68, Issue 1, 2009, Pages 106-115

  Barozzi, Nadia ^a   Sketris, Ingrid ^b   Cooke, Charmaine ^b   Tett, Susan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

COX 2 inhibitors; Drug utilization; International comparison; NSAIDs; Prescribing

Indexed keywords

CELECOXIB; DICLOFENAC; ETODOLAC; FENOPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LUMIRACOXIB; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; TENOXICAM; TIAPROFENIC ACID; VALDECOXIB;

ARTICLE; AUSTRALIA; CANADA; DRUG COST; DRUG USE; DRUG UTILIZATION; GASTROINTESTINAL SYMPTOM; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREND STUDY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUSTRALIA; CYCLOOXYGENASE 2 INHIBITORS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HUMANS; NOVA SCOTIA; PHYSICIAN'S PRACTICE PATTERNS;

EID: 67650932307     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03410.x     Document Type: Article

References (75)

1. Hawkins C, Hanks G. The gastoduodenal toxicity of nonsteroidal anti-inflammatory drugs. A review of the literature. J Pain Symptom Manage 2000 20 : 140 51.
2. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med 2001 110 : 4S 7S.
3. Tannenbaum H, Davis P, Russell AS, Atkinson MH, Maksymowych W, Huang SH, Bell M, Hawker GA, Juby A, Vanner S, Sibley J. An evidence-based approach toprescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Can Med Assoc J 1996 155 : 77 88.
4. Hermann M, Ruschitzka F. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Intern Med J 2006 36 : 308 19.
5. Kearney P, Baignent C, Godwin J, Halls H, Emerson J. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 332 : 1302 8.
6. Tannenbaum H, Bombardier C, Davis P, Russell A, Group TCCC. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006 33 : 1 3.
7. Therapeutic Guidelines: Rheumatology Writing Group. Therapeutic Guidelines: Rheumatology. Melbourne : Therapeutic Guidelines Ltd, 2006.
8. Barozzi N, Tett S. Use of non selective non steroidal anti-inflammatory drugs, COX-2 inhibitors and Paracetamol. In: APSA-ASCPT. Melbourne; 2005.
9. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 2004 328 : 1415 6.
10. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 331 : 1310 6.
11. Canadian Pharmacists Association. Submission to the Romanov Commission on the Future of Health Care Canada. CphA, 2001. Available at http://www. pharmacists.ca/content/about-cpha/whats-happening/government-affairs/pdf/ romanow.pdf (last accessed 27 May 2007).
12. Office of the Auditor General Canada. Management of Federal Drug Benefit Programs. OAG, 2004. Available at http://www.oag-bvg.gc.ca/domino/reports.nsf/ html/20041104ce.html (last accessed 5 June 2007).
13. Health Canada. National Pharmaceuticals Strategy. Health Canada, 2005. Available at http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/2005/2005-96bk2-e.html (last accessed 25 May 2007).
14. National Prescribing Service. Minimising the risk of using analgesic for musculoskeletal pain. NPS Newsletter 2003; 28.
15. National Prescribing Service. Proton Pump Inhibitors: Too Much of a Good Thing? Sydney : NPS, 2004.
16. Government of Nova Scotia. Nova Scotia's Health Insurance Plan. Government of Nova Scotia, 2006. Available at http://www.gov.ns.ca/health/msi/ (last accessed 24 April 2009).
17. Government of Nova Scotia. Nova Scotia Pharmacare Programs. The Nova Scotia Seniors' Pharmacare Program. Government of Nova Scotia, 2007. Available at http://gov.ns.ca/heal/pharmacare/pubs/Seniors-Information-Booklet-2007.pdf (last accessed 30 September 2007).
18. Government of Nova Scotia. Nova Scotia Pharmacare Formulary. Government of Nova Scotia, 2007. Available at http://www.gov.ns.ca/health/Pharmacare/ formulary.asp (last accessed 31 October 2007).
19. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with Ddds, 2007.
20. Barozzi N, Tett S. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Pharmacoepidemiol Drug Saf 2007 16 : 1184 91.
21. Curtis C, Langley CA, Marriott JF, Wilson KA. A comparison of antibiotic prescribing indicators and medicines management scoring in secondary care. Int J Pharm Pract 2003 11 : R54.
22. Gastroenterological Society of Australia. NSAID Therapy - Maximizing the Benefit, Minimizing the Risk. GESA, 2004. Available at http://www.gesa.org.au/ (last accessed 4 April 2009).
23. Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 2003 25 : S32 40.
24. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 2004 63 : 759 66.
25. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs - a meta analysis. Ann Intern Med 1991 115 : 787 96.
26. Chiroli S, Chinellato A, Didoni G, Mazzi S, Lucioni C. Utilisation pattern of nonspecific nonsteroidal anti-inflammatory drugs and COX-2 inhibitors in a local health service unit in northeast Italy. Clin Drug Investig 2003 23 : 751 60.
27. Bergman U, Popa C, Tomson Y, Wettermark B, Einarson T, Aberg H, Sjögvist F. Drug utilization 90% - a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol 1998 54 : 113 8 (PMID: 9626914).
28. Taylor D. Medicine in Europe - prescribing in Europe - Forces for change. BMJ 1992 304 : 239 42.
29. Bower K, Frail D, Twohig P, Putnam W. What influences seniors' choice of medications for osteoarthritis? Can Fam Physician 2006 52 : 342 6.
30. Chiropractic & Osteopathic College of Australasia. Celebrex Controversy. Chiropractic & Osteopathic College of Australasia, 2001. Available at http://www.coca.com.au/newsletter/2001/MAR0109a.htm (last accessed 5 May 2007).
31. Department of Health and Aging TGA. Status of Action on Products Containing Meloxicam. Department of Health and Aging TGA, 2005. Available at http://www.tga.gov.au/media/2005/050415-meloxicam.htm (last accessed 27 November 2007).
32. National Prescribing Service. Elevated Cardiovascular Risk with NSAIDs? RADAR, 2005. Available at http://www.npsradar.org.au/site.php?page= 1&content=/npsradar/content/nsaids.html (last accessed 27 November 2007).
33. Department of Health and Ageing. Regulator Takes Tough Action on Arthritis Drugs (*Amended). Therapeutic Good Administration, 2005. Available at http://www.tga.gov.au/media/2005/050225-cox2.htm (last accessed 19 March 2008).
34. Health Canada. Safety and Regulatory Information Regarding Celebrex® (Celecoxib), Bextra™ (Valdecoxib), and Meloxicam Subsequent to the Withdrawal of Vioxx® (Rofecoxib). Health Canada, 2004. Available at http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/-2004/2004-50bk1-e.html (last accessed 16 September 2007).
35. Health Ontario. Drugs Details. Health Ontario, 2007. Available at http://www.healthyontario.com/DrugDetails.aspx?brand-id=1963&brand-name= ratio-Meloxicam (last accessed 27 November 2007).
36. RxCC Rx Care Canada. Prescription Drugs. RxCC Rx Care Canada, 2004. Available at http://www.rxcarecanada.com/mobicox.asp?prodid=2030 (last accessed 27 November 2007).
37. The Arthritis Society. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). The Arthritis Society, 2006. Available at http://www.arthritis.ca/ tips%20for%20living/understanding%20medications/non%20steroidal/default.asp?s=1 (last accessed 27 November 2007).
38. Dalhousie Continuing Medical Education. Academic Detailing Service Resources. Osteoarthritis Management in 2002. Dalhousie Continuing Medical Education, 2002. Available at http://cme.medicine.dal.ca/ad-resources.htm#OA (last accessed 12 October 2007).
39. Yocum D, Fleischmann R, Dalgin P, Caldwell JR, Hall D, Roszko P. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. Arch Intern Med 2000 160 : 2947 54.
40. Singh G, Lanes S, Triadiafalopulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004 11 : 100 6.
41. Canadian Health Services Research Foundation, Kephart GC, Skedgel C, Sketris I, Grootendorst I, Hoar J, Sommers E. The Effect of Changes in Co-payment and Premium Policies on the Use of Prescription Drugs in the Nova Scotia Seniors' Pharmacare Program, 2003.
42. Blustein J. Drug coverage and drug purchases by medicare beneficiaries with hypertension. Health Aff (Millwood) 2000 19 : 219 30.
43. Huttin C. The use of prescription charges. Health Policy 1994 27 : 53 73.
44. Lundberg L, Johannesson M, Isacson DGL, Borgquist L. Effects of user charges on the use of prescription medicines in different socio-economic groups. Health Policy 1998 44 : 123 34.
45. Health Canada. Comments on the Report from Expert Advisory Panel on the Safety of COX-2 Selective Non-Steroidal Antiinflammatory Drugs (NSAIDS). 19 May 2006.
46. O'Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen DT, Forsetlund L, Bainbridge D, Freemantle N, Davis D, Haynes RB, Harvey E. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007 4 CD000409. DOI: 10.1002/14651858.CD000409.pub2.
47. Gjelstad S, Fetveit A, Straand J, Dalen I, Rognstad S, Lindbaek M. Can antibiotic prescriptions in respiratory tract infections be improved? A cluster-randomized educational intervention in general practice - The Prescription Peer Academic Detailing (Rx-PAD) Study [NCT00272155 BMC Health Serv Res 2006 6 : 75.
48. Hennessy S, Leonard CE, Yang W, Kimmel SE, Townsend RR, Wasserstein AG, Ten Have TR, Bilker WB. Effectiveness of a two-part educational intervention to improve hypertension control: a cluster-randomized trial. Pharmacotherapy 2006 26 : 1342 7.
49. Horn FE, Mandryk JA, Mackson JM, Wutzke SE, Weekes LM, Hyndman RJ. Measurement of changes in antihypertensive drug utilisation following primary care educational interventions. Pharmacoepidemiol Drug Saf 2007 16 : 297 308.
50. Taylor-Davis S, Smiciklas-Wright H, Warland R, Achterberg C, Jensen GL, Sayer A, Shannon B. Responses of older adults to theory-based nutrition newsletters. J Am Diet Assoc 2000 100 : 656 64.
51. Roughead E, Pratt N, Peck R, Gilbert A. Improving medication safety: influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners. Pharmacoepidemiol Drug Saf 2007 16 : 797 803.
52. Zwar N, Henderson J, Britt H, McGeechan K, Yeo G. Influencing antibiotic prescribing by prescriber feedback and management guidelines: a 5-year follow-up. Fam Pract 2002 19 : 12 7.
53. Lambert MF, Masters GA, Brent SL. Can mass media campaigns change antimicrobial prescribing? A regional evaluation study. J Antimicrob Chemother 2007 59 : 537 43.
54. Ioannidis G, Papaioannou A, Thabane L, Gafni A, Hodsman A, Kvern B, Johnstone D, Plumley N, Baldwin A, Doupe M, Katz A, Salach L, Adachi JD. Canadian Quality Circle pilot project in osteoporosis - rationale, methods, and feasibility. Can Fam Physician 2007 53 : 1694 700.
55. McCabe MP, Davison TE, George K. Effectiveness of staff training programs for behavioral problems among older people with dementia. Aging Ment Health 2007 11 : 505 19.
56. Monette J, Miller MA, Monette M, Laurier C, Boivin JF, Sourial N, Le Cruquel JP, Vandal A, Cotton-Montpetit M. Effect of an educational intervention on optimizing antibiotic prescribing in long-term care facilities. J Am Geriatr Soc 2007 55 : 1231 5.
57. Graham S, Hartzema A, Sketris I, Winterstein A. Effect of an academic detailing intervention on the utilization rate of cyclo-oxygenase-2 inhibitors. Ann Pharmacother 2008 42 : 749 56.
58. Furu K, Skurtveit S, Slørdal L. Use of selective COX-2 inhibitors in Norway before and after the Withdrawal of rofecoxib - Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2006 15 (Suppl. 1 S243 4.
59. Hoebert J, Stolk P, Belister S, Leufkens H, Martins A. The impact of the withdrawal of rofecoxib on the use of other analgesics and proton pump inhibitors - a time series analysis in Portugal. Pharmacoepidemiol Drug Saf 2006 15 (Suppl. 1 S166.
60. Schussel K, Schulz M. Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals. Pharmazie 2006 61 : 878 86.
61. Teeling M, Bennett K, O'Connor H, Feely J. How did the withdrawal of rofecoxib impact on prescribing of non-steroidal anti inflammatory drugs? Br J Clin Pharmacol 2006 61 : 637 8.
62. Verispan VONA. Top 200 Brand-name Drugs by Retail Dollars in 2005. Verispan, 2006. Available at http://drugtopics.modernmedicine.com/drugtopics/ data/articlestandard//drugtopics/082006/309440/article.pdf (last accessed 22 February 2008).
63. Williams D, Singh M, Hind C. The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. Br J Clin Pharmacol 2006 62 : 366 8.
64. Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of cox-2 inhibitor rofecoxib and valdecoxib: impact on NSAID and PPI prescriptions and expenditures. Curr Med Res Opin 2007 8 : 1859 66.
65. Kasman N, Badley E. Arthritis-related prescription medicines. In : Arthritis in Canada. An Ongoing Challenge, ed. Health Canada. Ottawa : Health Canada, 2003. Available at http://www.phac-aspc.gc.ca/publicat/ac/ac-9e-eng.php (last accessed 4 April 2009).
66. Coggon D, Rose G, Barker D. Ecological studies, 1997. Available at http://www.bmj.com/epidem/epid.6.html (last accessed 19 March 2008).
67. Cooke C, Nissen L, Sketris I, Tett S. Quantifying the use of the statin antilipemic drugs: comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia. Clin Ther 2005 27 : 497 508.
68. Tett S, Smith AJ, Sketris I, Cooke C, Gardner DM, Kisely S. A comparison of benzodiazepine and related drug use in Nova Scotia, Canada and Australia. 4th Annual Canadian Therapeutics Congress, 2007, Halifax Nova Scotia.
69. Agenzia Italiana del Farmaco. Prontuario Farmaceutico Nazionale. 2005.
70. PharmaCare. BCPharmaCare Newsletter 2005; 05: 1-3.
71. Nova Scotia Department of Community Services. Proton Pump Inhibitors - Policy changes. May Bulletin 2003.
72. National Prescribing Service. GORD and non-ulcer dyspepsia. NPS Newsletter 2001; 14.
73. National Prescribing Service. Proton Pump Newsletter Inhibitors. NPS 2006; 46.
74. Siracuse MV, Vuchetich PJ. Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska. Health Serv Res 2008 43 : 435 50.
75. LaPensee K. Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization. J Manag Care Pharm 2003 9 : 36 44.